Latest News - DexCom
Top Corporates Hub
DexCom
DexCom (DXCM) Reports Earnings Tomorrow: What To Expect
29.10.2025 03:03
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know.
ViCentra Strengthens Leadership Team to Accelerate Growth
28.10.2025 08:30
ViCentra, a European medical device company redefining insulin delivery for people with diabetes with the Kaleido insulin patch pump system, today announced two strategic senior leadership appointments following the company's recent $85 million Series D financing. Karen Baxter, former Vice President & General Manager at Dexcom, joins as Senior Vice President of Sales, Europe, and Jay Little, a long-time commercialization and market access executive at Medtronic Diabetes, takes on the newly creat
DexCom Earnings Preview: What to Expect
13.10.2025 15:15
DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.
William Blair Maintains Bullish Stance on DexCom (DXCM) Stock
08.10.2025 05:47
DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now. On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving a “Buy” rating. The analyst’s rating is backed by a combination of factors demonstrating its growth potential despite current concerns. The analyst noted that the MAUDE database, which […]
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm
07.10.2025 04:35
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
DexCom May Be The Most Underrated Growth Story In Healthcare
06.10.2025 06:39
DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory risks. Learn why DXCM stock is a buy.
United States Continuous Glucose Monitoring (CGM) Market Forecast 2025-2033: Focus on California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, Washington, New Jersey
01.10.2025 11:44
The United States Continuous Glucose Monitoring (CGM) Market is projected to surge from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, growing at a CAGR of 8.36% from 2025-2033. Key growth drivers include the rising prevalence of diabetes, technological advancements, enhanced insurance coverage, and increased awareness. Major players like Dexcom, Abbott, and Medtronic lead the market with user-friendly, accurate devices. The integration of CGMs is pivotal for proactive diabetes management
1 Growth Stock Down 40% to Buy Hand Over Fist Right Now
23.09.2025 13:45
It is dealing with some short-term issues, but its prospects remain bright.
Stock Market Today: Dow, S&P Aim For New Highs; Gold Stocks Shine (Live Coverage)
19.09.2025 18:05
Major stock indexes rise Friday as Wall Street awaits news from President Donald Trump's call with China's Xi Jinping.
Why DexCom (DXCM) Shares Are Trading Lower Today
19.09.2025 17:11
Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring device, questioned its accounting, and highlighted an executive exodus.
1 Large-Cap Stock Worth Your Attention and 2 We Find Risky
18.09.2025 05:32
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Wall Street is Bullish on DexCom (DXCM), Here’s Why
16.09.2025 16:42
DexCom, Inc. (NASDAQ:DXCM) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. Wall Street is bullish on DexCom, Inc. (NASDAQ:DXCM) after the company topped revenue and EPS estimates during its fiscal second quarter of 2025. The company posted $1.16 billion in revenue, up 15.21% year-over-year and ahead of consensus by $32.49 […]
Insulet names new CFO; Dexcom CEO on leave
16.09.2025 12:36
Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
15.09.2025 08:15
VIENNA, September 15, 2025--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference.
DexCom Insiders Sold US$11m Of Shares Suggesting Hesitancy
25.08.2025 14:00
Many DexCom, Inc. ( NASDAQ:DXCM ) insiders ditched their stock over the past year, which may be of interest to the...
DexCom (NASDAQ:DXCM) Shareholders Will Want The ROCE Trajectory To Continue
21.08.2025 10:33
NasdaqGS:DXCM 1 Year Share Price vs Fair Value Explore DexCom's Fair Values from the Community and select yours If we...
FriskaAi and Dexcom Enter CGM Data Integration Agreement
13.08.2025 13:30
ARLINGTON, VA / ACCESS Newswire / August 13, 2025 /FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the ...
DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook
13.08.2025 04:05
Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year’s revenue to be around $4.61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts’ consensus estimates.
5 Revealing Analyst Questions From DexCom’s Q2 Earnings Call
13.08.2025 03:38
DexCom’s second quarter 2025 results saw the company surpass Wall Street’s revenue and earnings expectations, though the market’s immediate reaction was notably negative. Management attributed the quarter’s strong performance to sustained demand from both new and existing customers, with particular momentum among the type 2 non-insulin diabetes population. CEO Kevin Sayer emphasized DexCom’s expanding coverage through the three largest pharmacy benefit managers (PBMs), which now provides reimbur
Health Care Roundup: Market Talk
12.08.2025 10:20
Find insight on Novartis, Eli Lily, Dexcom and more in the latest Market Talks covering Health Care.